Neomycin drug interactions: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
 
(5 intermediate revisions by the same user not shown)
Line 7: Line 7:
Caution should be taken in concurrent or serial use of other neurotoxic and/or nephrotoxic drugs because of possible enhancement of the [[nephrotoxicity]] and/or [[ototoxicity]] of neomycin (see boxed WARNINGS ).
Caution should be taken in concurrent or serial use of other neurotoxic and/or nephrotoxic drugs because of possible enhancement of the [[nephrotoxicity]] and/or [[ototoxicity]] of neomycin (see boxed WARNINGS ).


Caution should also be taken in concurrent or serial use of other aminoglycosides and polymyxins because they may enhance neomycin's nephrotoxicity and/or ototoxicity and potentiate neomycin's neuromuscular blocking effects.
Caution should also be taken in concurrent or serial use of other aminoglycosides and [[polymyxin]]s because they may enhance neomycin's [[nephrotoxicity]] and/or [[ototoxicity]] and potentiate neomycin's neuromuscular blocking effects.


Oral neomycin inhibits the gastrointestinal absorption of [[penicillin V]], oral vitamin B-12, [[methotrexate]] and [[5-fluorourcil]]. The gastrointestinal absorption of [[digoxin]] also appears to be inhibited. Therefore, digoxin serum levels should be monitored.
Oral neomycin inhibits the gastrointestinal absorption of [[penicillin V]], oral [[vitamin B12]], [[methotrexate]] and 5-[[fluorouracil]]. The gastrointestinal absorption of [[digoxin]] also appears to be inhibited. Therefore, digoxin serum levels should be monitored.


Oral neomycin may enhance the effect of coumarin in anticoagulants by decreasing [[vitamin K]] availability.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = NEO-FRADIN (NEOMYCIN SULFATE) SOLUTION [X-GEN PHARMACEUTICALS, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aea1d3e4-604a-4680-91e2-cce6a128a1b5 | publisher =  | date =  | accessdate = }}</ref>
Oral neomycin may enhance the effect of [[coumarin]] in anticoagulants by decreasing [[vitamin K]] availability.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = NEO-FRADIN (NEOMYCIN SULFATE) SOLUTION [X-GEN PHARMACEUTICALS, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aea1d3e4-604a-4680-91e2-cce6a128a1b5 | publisher =  | date =  | accessdate = }}</ref>


==References==
==References==

Latest revision as of 17:26, 7 January 2014

Neomycin
NEO-FRADIN® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Drug Interactions

Caution should be taken in concurrent or serial use of other neurotoxic and/or nephrotoxic drugs because of possible enhancement of the nephrotoxicity and/or ototoxicity of neomycin (see boxed WARNINGS ).

Caution should also be taken in concurrent or serial use of other aminoglycosides and polymyxins because they may enhance neomycin's nephrotoxicity and/or ototoxicity and potentiate neomycin's neuromuscular blocking effects.

Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B12, methotrexate and 5-fluorouracil. The gastrointestinal absorption of digoxin also appears to be inhibited. Therefore, digoxin serum levels should be monitored.

Oral neomycin may enhance the effect of coumarin in anticoagulants by decreasing vitamin K availability.[1]

References

  1. "NEO-FRADIN (NEOMYCIN SULFATE) SOLUTION [X-GEN PHARMACEUTICALS, INC.]".

Adapted from the FDA Package Insert.